Search Results - Douglas B. Johnson

Cost assessment in melanoma clinical trials: A cross-sectional study by Rachel S. Goodman, MBA, Desmond C. Garner, BS, Stefan Koester, BS, J. Randall Patrinely, Jr., MD, MBA, Anna K. Dewan, MD, Douglas B. Johnson, MD, MSCI

Connect to this object online.

Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Gro... by Bernardo L. Rapoport, Bernardo L. Rapoport, Bernardo L. Rapoport, Vickie R. Shannon, Tim Cooksley, Tim Cooksley, Tim Cooksley, Douglas B. Johnson, Lindsay Anderson, Ada G. Blidner, Gregory R. Tintinger, Ronald Anderson, Ronald Anderson

Connect to this object online.

Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort studyCapsule Summary by Xue Bai, MD, Aleigha R. Lawless, BS, Juliane A. Czapla, MS, Stefanie C. Gerstberger, MD, PhD, Benjamin C. Park, MD, Seungyeon Jung, BA, Rebecca Johnson, MN, Naoya Yamazaki, MD, PhD, Dai Ogata, MD, PhD, Yoshiyasu Umeda, MD, Caili Li, MB, Jun Guo, MD, PhD, Keith T. Flaherty, MD, Yasuhiro Nakamura, MD, PhD, Kenjiro Namikawa, MD, PhD, Georgina V. Long, MBBS, PhD, Alexander M. Menzies, MBBS, PhD, Douglas B. Johnson, MD, Ryan J. Sullivan, MD, Genevieve M. Boland, MD, PhD, Lu Si, MD

Connect to this object online.